Icos Corporation

G.d. Searle & Company

Kineta, Inc.

Indiana University

Oculon Corporation

Deltagen Research Labs, LLC

Searle & Co.

Fowler, Kerry W.

Chorvat, Robert J.

Snyder, James P.

Kerry W Fowler

Amy Oliver

Edward A Kesicki

Joshua O Odingo

Danwen Huang

Timothy J Martins

Jennifer Anne Treiberg

Fuqiang Ruan

Hua Chee Ooi

Kamal Deep Puri

Laurence Edward Burgess

Stephen T Schlachter

John Joseph Gaudino

Bradley Jon Newhouse

Zachary S Jones

Shawn P Iadonato

Kristin M Bedard

Carmen C Hertel

Myra Wang Imanaka

Bipinchandra N Desai

Robert J Chorvat

Stephen T Schlacter

Jaipal Singh

Richard A Mueller

Stevan Wakefield Djuric

Mark W Orme

John Patrick McKearn

Alan E Moormann

James P Snyder

Jaimie Karyn Rueter

Louis J Theodore

Chi-Dean Liang

Qin Jiang

Pavel E Zhichkin

Susan A Gregory

John I Clark

Graham Beaton

Kurt J Rorig

Wilna J Moree

Russell Dahl

David L McElligott

John M Farah, Jr

Erik Christenson

Phyllis S Goldman

David John Fairfax

Helge A Reisch

Anthony J Demaggio

Dan Herendeen

Jaimie E Bertino

Ikenna Madu

Lisa H Bourdon

Shari Kaiser

Ren Hua Song

Ernesto J Muñoz

Amy R Oliver

Disclosed are compounds that can modulate DDAH and the amount of asymmetric dimethylarginine (ADMA) in a subject. Also provided are pharmaceutical compositions comprising these compounds, as well as methods of using these compositions to treat and/or prevent diseases associated with elevated or low levels of DDAH and ADMA.

Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease

Compounds that inhibit PI3K&#x3b4; activity, including compounds that selectively inhibit PI3K&#x3b4; activity, are disclosed. Methods of preparing such compounds are also disclosed, including the preparation and use of the compound tert-butyl (S)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate of formula (110) as a precursor to synthesize an exemplary compound disclosed in this application, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&#x3b4;) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K&#x3b4; plays a role in leukocyte function, using the compounds also are disclosed. 

Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof

Compounds that inhibit PI3K&#x3b4; activity, including compounds that selectively inhibit PI3K&#x3b4; activity, are disclosed. Methods of preparing such compounds are also disclosed, including the use of (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one as a precursor to synthesize an exemplary compound disclosed in this application, (S)-2-(1-((9H-purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&#x3b4;) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K&#x3b4; plays a role in leukocyte function, using the compounds also are disclosed.

(S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta

Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.

Anti-viral compounds

Disclosed herein are compounds, pharmaceutical compositions, and related methods for the treatment of viral infection, including RNA viral infection in subjects. The compounds, pharmaceutical compositions, and methods can modulate the innate immune antiviral response in vertebrate cells, including activating the RIG-I pathway.

Anti-viral compounds, pharmaceutical compositions, and methods of use thereof

Compounds that inhibit PI3K&#x3b4; activity, including compounds that selectively inhibit PI3K&#x3b4; activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&#x3b4;) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K&#x3b4; plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below: 

5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta

Compounds that inhibit PI3K&#x3b4; activity, including compounds that selectively inhibit PI3K&#x3b4; activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&#x3b4;) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K&#x3b4; plays a role in leukocyte function, using the compounds also are disclosed. Exemplary compounds disclosed in this application are shown below: 

5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta

5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta

Compounds that inhibit PI3K&#x3b4; activity, including compounds that selectively inhibit PI3K&#x3b4; activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K&#x3b4;) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K&#x3b4; plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below. 

6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta

The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3K&#x3b4; activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses.

Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta

Compounds that inhibit PI3K&#x3b4; activity, including compounds that selectively inhibit PI3K&#x3b4; activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform PI3K&#x3b4; activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3K&#x3b4; plays a role in leukocyte function, using the compounds also are disclosed. An exemplary compound disclosed in this application is shown below. 

6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta

Compounds that inhibit P13K&#x3b4; activity, including compounds that selectively inhibit P13K&#x3b4; activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (P13K&#x3b4;) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which P13K&#x3b4; plays a role in leukocyte function, using the compounds also are disclosed.

Growing community of inventors

Seattle, WA, United States of America

Kerry W Fowler